Dr. Sy Pretorius is a Boston-based executive with nearly 30 years of experience in the pharmaceutical industry.
He has a unique combination of deep expertise in drug development and commercialization. Sy has successfully held C-suite roles in both publicly listed and private equity-backed global organizations across different countries.
Before joining Ergomed as CEO, Sy was COO at EVERSANA, focusing on drug and device commercialization services. Prior to that, he served as President, Clinical Development and Chief Medical Officer at PAREXEL, where he oversaw a $3.6 billion global P&L and led more than 16,000 employees worldwide.
Sy currently serves on the Board of Ergomed and Tekton Research and is an advisory board member for Automata. He previously held board appointments at Vault Clinical and FARMOVS. Recognized in the PharmaVOICE 100 most inspiring leaders in the pharmaceutical industry list in 2017 and 2023, Sy is also an honorary Fellow of the Faculty of Pharmaceutical Medicine in the UK and a lecturer in drug development at several institutions, including Harvard Medical School.
Sy is a licensed Medical Doctor with master’s degrees in Clinical Pharmacology, Business Administration, and the Management of Drug Development from the University of Southern California.
